Page last updated: 2024-11-06

allura red ac dye

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Allura Red AC dye, also known as FD&C Red 40, is a synthetic azo dye widely used in food, cosmetics, and pharmaceuticals. It is a bright red powder that is soluble in water. Allura Red AC dye is synthesized through a multi-step process involving diazotization of sulfanilic acid and coupling with N-ethyl-N-(2-hydroxyethyl)-m-toluidine. The dye exhibits a strong absorbance maximum at 504 nm, contributing to its vibrant red color. In food applications, Allura Red AC dye is used to impart color to beverages, candies, and other food products. It is also used in cosmetics as a color additive in lipstick, eyeshadow, and nail polish. The dye has been the subject of research concerning its potential effects on health, particularly in relation to allergic reactions and hypersensitivity. Studies have explored the potential for Allura Red AC dye to trigger allergic responses in susceptible individuals. The dye's potential carcinogenic properties have also been investigated, with some studies suggesting a possible link to cancer development. However, the evidence remains inconclusive and requires further research. Due to these potential concerns, the use of Allura Red AC dye is regulated in many countries, with limitations imposed on its concentration in food and cosmetic products. Continued research is necessary to further understand the potential health effects of Allura Red AC dye and to ensure its safe use in various applications.'

Allura Red AC Dye: new monoazo dye proposed as color additive in various food products; RN given refers to di-Na salt; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID33258
CHEMBL ID174821
CHEMBL ID3188816
CHEBI ID172687
SCHEMBL ID340786
SCHEMBL ID324089
MeSH IDM0047789

Synonyms (100)

Synonym
disodium;6-hydroxy-5-[(2-methoxy-5-methyl-4-sulonatophenyl)diazenyl]naphthalene-2-sulonate
CHEBI:172687
food red 17
2-naphthalenesulfonic acid, 6-hydroxy-5-((6-methoxy-4-sulfo-m-tolyl)azo)-, disodium salt
hsdb 7260
fd & c red no. 40
einecs 247-368-0
c. i. 16035
ccris 3493
2-naphthalenesulfonic acid, 6-hydroxy-5-((2-methoxy-5-methyl-4-sulfophenyl)azo)-, disodium salt
curry red
allura red c.i.16035
6-hydroxy-5-((2-methoxy-5-methyl-4-sulfophenyl)azo)-2-naphthalene- sulfonic acid, disodium salt
fd and c red no. 40
ci 16035
disodium 6-hydroxy-5-((6-methoxy-4-sulfo-m-tolyl)azo)-2-naphthalenesulfonate
allura red ac
disodium 6-hydroxy-5-((2-methoxy-5-methyl-4-sulfophenyl)azo)-2-naphthalenesulfonate
fd&c red no. 40
allura red
disodium 6-hydroxy-5-((2-methoxy-4-sulphonato-m-tolyl)azo)naphthalene-2-sulphonate
c.i. food red 17
food red no. 40
red no. 40
allura red ac dye
disodium 6-hydroxy-5-((2-methoxy-5-methyl-4-sulfophenyl)azo)-2-naphthalene- sulfonate
allura red ac, dye content 80 %
25956-17-6
2-naphthalenesulfonic acid, 6-hydroxy-5-[(2-methoxy-5-methyl-4-sulfophenyl)azo]-, disodium salt
c.i.16035
disodium 6-hydroxy-5-[(e)-(2-methoxy-5-methyl-4-sulfonatophenyl)diazenyl]naphthalene-2-sulfonate
A0943
fd and c red no.40
FT-0661496
CHEMBL174821 ,
e129
F0325
NCGC00254423-01
tox21_300393
dtxsid4024436 ,
cas-25956-17-6
dtxcid504436
wzb9127xoa ,
2-naphthalenesulfonic acid, 6-hydroxy-5-(2-(2-methoxy-5-methyl-4-sulfophenyl)diazenyl)-, sodium salt (1:2)
japan food red no. 40
japan red 40
e 129
red 40
fdc red 40
unii-wzb9127xoa
allura red 40
ec 247-368-0
fancy red
fdc red 40 dye
fd&c red no.40
allura red ac [mart.]
ci 16035 [inci]
f d & c red no. 40
f d & c red #40 lake [vandf]
ci-(1975)no.16035
allura red ac dye [hsdb]
e-129
allura red ac [mi]
fd&c red no. 40 [ii]
disodium 6-hydroxy-5-((e)-(2-methoxy-5-methyl-4-sulfonatophenyl)diazenyl)naphthalene-2-sulfonate
curry red [inci]
red 40 [inci]
6-hydroxy-5-((2-methoxy-5-methyl-4-sulfophenyl)azo)-2-naphthalenesulfonic acid
ins-129
allura red [fcc]
ins no.129
f d & c red #40 [vandf]
fdc red no. 40
fd&c red 40
fd&c red no. 40 [fcc]
ci-food red 17
2-naphthalenesulfonic acid, 6-hydroxy-5-((e)-(2-methoxy-5-methyl-4-sulfophenyl)azo)-, disodium salt
AKOS015903081
BP-31017
AKOS025310826
SCHEMBL340786
SCHEMBL324089
CEZCCHQBSQPRMU-UHFFFAOYSA-L
CHEMBL3188816
mfcd00059526
allura red ac, analytical standard
J-016192
al-lura red ac
sodium 6-hydroxy-5-((2-methoxy-5-methyl-4-sulfonatophenyl)diazenyl)naphthalene-2-sulfonate
Q419895
ci 16035; food red 17; fancy red;
2-naphthalenesulfonic acid, 6-hydroxy-5-[2-(2-methoxy-5-methyl-4-sulfophenyl)diazenyl]-, sodium salt (1:2)
D70160
disodium;(5z)-5-[(2-methoxy-5-methyl-4-sulfonatophenyl)hydrazinylidene]-6-oxonaphthalene-2-sulfonate
allura red ac 100 microg/ml in water
sodium (e)-6-hydroxy-5-((2-methoxy-5-methyl-4-sulfonatophenyl)diazenyl)naphthalene-2-sulfonate
disodium;6-hydroxy-5-[(2-methoxy-5-methyl-4-sulfonatophenyl)diazenyl]naphthalene-2-sulfonate
1016649-41-4
DTXSID70860355
763 - colours

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No compound-related adverse effects were observed."( Lifetime toxicity/carcinogenicity studies of FD & C red no. 40 (allura red) in mice.
Borzelleca, JF; Olson, JW; Reno, FE, 1991
)
0.28
" No compound-related adverse effects were observed, except for a reduction in body weight in high-dose females at the end of the study."( Lifetime toxicity/carcinogenicity study of FD & C Red No. 40 (allura red) in Sprague-Dawley rats.
Borzelleca, JF; Olson, JW; Reno, FE, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
" The results showed a trend by which the rate of absorption of (14)C-glucose followed that observed in the corresponding in vitro release studies, providing the first indication that the nanostructure of these materials may provide the ability to tailor the absorption kinetics of hydrophilic drugs in vivo, and hence form the basis of a new drug delivery system."( Nanostructure of liquid crystalline matrix determines in vitro sustained release and in vivo oral absorption kinetics for hydrophilic model drugs.
Boyd, BJ; Hanley, T; Lee, KW; Nguyen, TH, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Dosage effects may be sought in a variety of ways, including alternative procedures for identifying progressive dosage effects."( Assessing laboratory evidence for neoplastic activity.
Mantel, N, 1980
)
0.26
" There were few adverse effects of Allura Red AC on either litter size or weight, and ratio of male to female was significantly reduced in the lowest dosed group."( Reproductive and neurobehavioral effects of Allura Red AC administered to mice in the diet.
Tanaka, T, 1994
)
0.29
" The values of percentage removal show that the adsorption capacity increases with time of contact and dosage of chitosan-TPP, but red dye adsorption is mainly influenced by pH level."( Adsorption of allura red dye by cross-linked chitosan from shrimp waste.
Correa-Murrieta, MA; López-Cervantes, J; Sánchez-Duarte, RG; Sánchez-Machado, DI, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency63.26090.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency70.97990.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency15.68920.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency31.45370.000221.22318,912.5098AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency26.79200.001022.650876.6163AID1224838; AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.93580.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency34.16720.000229.305416,493.5996AID1259244; AID1259248; AID743079; AID743080; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency27.30600.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency52.95890.001628.015177.1139AID1259385; AID1259395
Histone H2A.xCricetulus griseus (Chinese hamster)Potency42.07530.039147.5451146.8240AID1224845; AID1224896
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency57.80670.000323.4451159.6830AID743065; AID743067
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency27.30600.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency27.30600.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)33.00000.00053.49849.7600AID157217
Tyrosine-protein phosphatase 1Saccharomyces cerevisiae S288CIC50 (µMol)410.00001.20004.30007.4000AID220230
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID99424Inhibition of human Leukocyte Antigen Related(LAR) protein tyrosine phosphatase D12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID157217Inhibition of human PTPase 1B2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID220230Inhibitory activity against Saccharomyces cerevisiae Tyrosine phosphatase 12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (11.70)18.7374
1990's7 (7.45)18.2507
2000's15 (15.96)29.6817
2010's44 (46.81)24.3611
2020's17 (18.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.92 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index133.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (1.98%)4.05%
Observational0 (0.00%)0.25%
Other99 (98.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]